- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Evaxion Biotech AS (EVAX)
Evaxion Biotech AS stock price live, this page displays NASDAQ EVAX stock exchange data. View the EVAX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Evaxion Biotech AS real time stock price chart below.
What Is the Evaxion Biotech AS Stock Price Today?
The Evaxion Biotech AS stock price today is 2.920.
What Is the Stock Symbol for Evaxion Biotech AS?
The stock symbol for Evaxion Biotech AS is ""EVAX.""
What Stock Exchange Does Evaxion Biotech AS Trade On?
Evaxion Biotech AS is listed and trades on the NASDAQ stock exchange.
Is Evaxion Biotech AS a Good Stock to Buy?
Determining whether Evaxion Biotech AS—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the EVAX quote. (ISIN: US29970R3030)
What Is the Evaxion Biotech AS Stock Price Today?
The Evaxion Biotech AS stock price today is 2.920.
What Is the Stock Symbol for Evaxion Biotech AS?
The stock symbol for Evaxion Biotech AS is ""EVAX.""
What Stock Exchange Does Evaxion Biotech AS Trade On?
Evaxion Biotech AS is listed and trades on the NASDAQ stock exchange.
Is Evaxion Biotech AS a Good Stock to Buy?
Determining whether Evaxion Biotech AS—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the EVAX quote. (ISIN: US29970R3030)
NASDAQ
Currency in USD
Fair Value
An estimate of a Evaxion Biotech AS's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.710
3.025
52 wk Range
1.200
17.750
EVAX Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
EVAX is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Evaxion Biotech AS's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.7103.025
52 wk Range
1.20017.750
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
EVAX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Evaxion Biotech AS's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Strong Buy
Price Target
13.250
Upside
+353.77%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Net income is expected to drop this year
- Form 6K Evaxion Biotech AS For: 26 July
- Investing.com
- Form 6K Evaxion Biotech AS For: 2 July
- Investing.com
- Form 6K Evaxion Biotech AS For: 26 July
- Investing.com
- Form 6K Evaxion Biotech AS For: 11 July
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Evaxion Biotech AS Company Profile
Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based cancer vaccine that has completed Phase 1/2a trial to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers, including non-small cell lung cancer. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, a viral vaccine product candidate for targeting Cytomegalovirus. The company was formerly known as Evaxion Biotech A/S and changed its name to Evaxion A/S in May 2025. Evaxion A/S was incorporated in 2008 and is based in Horsholm, Denmark.
Evaxion Biotech AS Earnings Call Summary for Q2/2025
- Cash position at $14.7M, runway to mid-2026; operating loss reduced to $4.3M from $4.6M YoY
- Strategic partnerships, including Gates Foundation, central to growth; potential MSD collaboration in 2025
- New vaccine candidates EVX004 and EVX-D1 highlight expanding R&D pipeline
- Analyst consensus shows strong buy recommendations; price targets $6-$19.75
- Market challenges persist, impacting deal execution; focus on AI-driven vaccine development continues
Last Updated: 21/08/2025, 11:32
Read Full TranscriptCompare EVAX to Peers and Sector
Metrics to compare | EVAX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipEVAXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.5x | −0.4x | −0.6x | |
PEG Ratio | −0.02 | −0.01 | 0.00 | |
Price/Book | 3.0x | 1.7x | 2.6x | |
Price / LTM Sales | 5.8x | 7.3x | 3.3x | |
Upside (Analyst Target) | 379.5% | 350.4% | 37.8% | |
Fair Value Upside | Unlock | 33.5% | 4.3% | Unlock |
Analyst Ratings
2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 13.250
(+353.77% Upside)
Earnings
Latest Release
Aug 14, 2025
EPS / Forecast
-1.00 / -0.45
Revenue / Forecast
37.00K / --
People Also Watch
FAQ
What Stock Exchange Does Evaxion Biotech AS Trade On?
Evaxion Biotech AS is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Evaxion Biotech AS?
The stock symbol for Evaxion Biotech AS is "EVAX."
What Is the Evaxion Biotech AS Market Cap?
As of today, Evaxion Biotech AS market cap is 18.44M.
What Is Evaxion Biotech AS's Earnings Per Share (TTM)?
The Evaxion Biotech AS EPS (TTM) is -4.45.
From a Technical Analysis Perspective, Is EVAX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Evaxion Biotech AS Stock Split?
Evaxion Biotech AS has split 2 times.
How Many Employees Does Evaxion Biotech AS Have?
Evaxion Biotech AS has 46 employees.
What is the current trading status of Evaxion Biotech AS (EVAX)?
As of 06 Sept 2025, Evaxion Biotech AS (EVAX) is trading at a price of 2.920, with a previous close of 2.70. The stock has fluctuated within a day range of 2.710 to 3.025, while its 52-week range spans from 1.200 to 17.750.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.